Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 18:4:5336.
doi: 10.1038/srep05336.

Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis

Affiliations

Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis

Amiq Gazdhar et al. Sci Rep. .

Abstract

Reactive oxygen species (ROS) have been implemented in the etiology of pulmonary fibrosis (PF) in systemic sclerosis. In the bleomycin model, we evaluated the role of acquired mutations in mitochondrial DNA (mtDNA) and respiratory chain defects as a trigger of ROS formation and fibrogenesis. Adult male Wistar rats received a single intratracheal instillation of bleomycin and their lungs were examined at different time points. Ashcroft scores, collagen and TGFβ1 levels documented a delayed onset of PF by day 14. In contrast, increased malon dialdehyde as a marker of ROS formation was detectable as early as 24 hours after bleomycin instillation and continued to increase. At day 7, lung tissue acquired significant amounts of mtDNA deletions, translating into a significant dysfunction of mtDNA-encoded, but not nucleus-encoded respiratory chain subunits. mtDNA deletions and markers of mtDNA-encoded respiratory chain dysfunction significantly correlated with pulmonary TGFβ1 concentrations and predicted PF in a multivariate model.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Simplified hypothesis of mitochondrial involvement in the pathogenesis of bleomycin induced PF.
Bleomycin induces ROS that are perpetuated by positive feedback loops involving respiratory impairment and mitochondrial mutagenesis. ROS, respiratory chain dysfunction, or a combination of both, then induce TGFβ1 and interstitial lung disease.
Figure 2
Figure 2. Effects of bleomycin on lung histology.
Representative electron micrographs (A, B) demonstrate mitochondrial enlargement, disrupted crystal architecture and intracytoplasmic vacuoles in an alveolar epithelial cell at day 14. Panels C and D demonstrate depressed COX activity in pulmonary tissue at day 14 (brown stain in COX/SDH histochemistry) and an upregulation of SDH activity (blue stain) not visible at day 0 (insert in panel D). Panels E and F show the expression of αSMA. In normal lung, brown staining was only observed in the smooth muscle around the airways (E); a representative slide of lung tissue 14 days after bleomycin however documents excess αSMA expression in the thickened interstitial space (F). Magnification bars: 4 μm (A,B), 40 μm (C,D, insert D); 100 μm (E,F).
Figure 3
Figure 3. Correlations between PF, pulmonary TGFβ1 content, mitochondrial mutagenesis and mitochondrial function.

Similar articles

Cited by

References

    1. Tyndall A. J. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases 69, 1809–1815, 10.1136/ard.2009.114264 (2010). - PubMed
    1. Gross T. J. & Hunninghake G. W. Idiopathic pulmonary fibrosis. N Engl J Med 345, 517–525, 10.1056/NEJMra003200 (2001). - PubMed
    1. King T. E. Jr, Pardo A. & Selman M. Idiopathic pulmonary fibrosis. Lancet 378, 1949–1961, 10.1016/S0140-6736(11)60052-4 (2011). - PubMed
    1. Daniels C. E. et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181, 604–610, 10.1164/rccm.200906-0964OC (2010). - PubMed
    1. Tashkin D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354, 2655–2666, 10.1056/NEJMoa055120 (2006). - PubMed

MeSH terms